A maladaptive stress response might be amenable to behavioral or other interventions to lower future CV risk, say researchers ...

Task force members say that continued collection of data will help build credibility of what is “fair market value” for ...

This year’s report shows risk factors on the rise, enduring racial and geographic gaps, and clues to the global picture, too.

New data from US centers suggest some overtesting in patients without chest pain, and undertesting in those who do.

The ability to diagnose MI was better with troponin I, but T better predicted mortality. Both tests have strengths, ...

These latest data reinforce years of smaller studies, but whether they should change practice is a matter of debate.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

A study suggests that those under age 65 may need no restrictions at all, but more data would help clarify the issue.

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

Underrepresentation of women as participants and researchers in CV clinical trials remains a problem, asserts a review ...

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds ...